0001593968-23-000303.txt : 20230213
0001593968-23-000303.hdr.sgml : 20230213
20230213163618
ACCESSION NUMBER: 0001593968-23-000303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230209
FILED AS OF DATE: 20230213
DATE AS OF CHANGE: 20230213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brannan Stephen K.
CENTRAL INDEX KEY: 0001777631
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 23619125
MAIL ADDRESS:
STREET 1: C/O KARUNA THERAPEUTICS, INC.
STREET 2: 33 ARCH STREET, SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
primary_01.xml
PRIMARY DOCUMENT
X0306
4
2023-02-09
0001771917
Karuna Therapeutics, Inc.
KRTX
0001777631
Brannan Stephen K.
C/O KARUNA THERAPEUTICS, INC.
99 HIGH STREET, 26TH FLOOR
BOSTON
MA
02110
false
true
false
false
Chief Medical Officer
Common Stock
2023-02-09
4
M
false
5000
5.45
A
20000
D
Common Stock
2023-02-09
4
S
false
5000
192.37
D
15000
D
Common Stock
2023-02-09
4
A
false
8650
0
A
23650
D
Option (right to buy)
5.45
2023-02-09
4
M
false
5000
0
D
2027-06-01
Common Stock
5000
29677
D
Option (right to buy)
187.26
2023-02-09
4
A
false
17350
0
A
2033-02-08
Common Stock
17350
17350
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
/s/ Troy Ignelzi, Attorney-in-Fact
2023-02-13